PUBLISHER: Grand View Research | PRODUCT CODE: 1268645
PUBLISHER: Grand View Research | PRODUCT CODE: 1268645
The global veterinary pharmacovigilance market size is expected to reach USD 1.89 billion by 2030, registering a CAGR of 13.49% from 2023 to 2030, according to a new report by Grand View Research, Inc. The market is driven by several factors, including the increasing incidence of adverse drug reactions in animals, the rising adoption of companion animals, and the growing demand for animal-derived food products. Additionally, the increasing regulatory scrutiny and the need for stringent safety standards have led to the development of new pharmacovigilance technologies and tools. Accenture for instance, offers a range of Veterinary Vigilance services that include ICSR Case Processing , VeDDRA Coding, Signal Detection, Literature Management, EvVetMPD support, and Regulatory Intelligence. Growing industry requirements for aggregate reporting, expedited reporting, and management of signals are expected to propel the market growth in the coming years.
The COVID-19 pandemic has had both negative and positive impacts on the animal health market While it has created challenges, it has also created opportunities for companies to adapt and innovate, and has highlighted the importance of monitoring the safety and efficacy of animal health products in the context of global health crises. This supported the awareness and adoption of veterinary pharmacovigilance solutions. The field is an emerging sector within the animal healthcare market. It involves monitoring the safety and effectiveness of veterinary medicines, vaccines, and other animal health products, and reporting any adverse reactions or incidents that may occur. This information is then used to improve the safety and quality of these products and to protect animal health.With the growing concern for animal welfare and the increasing demand for animal-based food products, the market has gained significant attention in recent years.
Initiatives by key market participants is another factor fueling the market growth. In June 2018, Medfiles opened a new office in Japan to cater to European and Japanese clients with a range of services. These include pharmacovigilance, clinical trials, and analytical services, among others. In February 2022, Ennov, a key market player opened a new office in the U.S. in response to successful growth in the North American market. This expanded the company's global footprint with a focus on building its pharmacovigilance capabilities. Ennov's pharmacovigilance offerings include case intake, triage, signal detection and management for customers from human and veterinary life sciences market.